MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Deferoxamine mesylate

CAS No. : 138-14⁻⁷

MCE 国际站：Deferoxamine mesylate

产品活性：Deferoxamine mesylate是一种铁螯合剂，可将游离铁与稳定的复合物结合，防止其发生化学反应。

研究领域：Autophagy | Neuronal Signaling | Apoptosis

作用靶点：Autophagy | Amyloid-β | Mitophagy | Ferroptosis

In Vitro: Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals. Deferoxamine (5 µM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 µM and 100 µM deferoxamine. Deferoxamine (5 µM-100 µM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs. Deferoxamine (30, 60, 120 µM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs.

In Vivo: Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental. Ten µL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Neuronal Signaling Compound Library | FDA-Approved Drug Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Diabetes Related Compound Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Anti-COVID-19 Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Alzheimer’s Disease Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | 3-Methyladenine | Erastin | Ferrostatin-1 | Cisplatin | Doxorubicin hydrochloride | Cycloheximide | RSL3 | SB 203580 | Acetylcysteine | SP600125 | Dexamethasone | Metformin hydrochloride | Necrostatin-1 | U0126-EtOH | Etoposide | AICAR | DAPT | Brefeldin A | Rosiglitazone | Resveratrol | SB 202190 | Quercetin | Melatonin | Curcumin | Valproic acid | Sunitinib | Tanespimycin | Hemin | (-)-Epigallocatechin Gallate | TBHQ

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。